News Releases

Pharming Group N.V. presents its preliminary (unaudited) financial report for the first six months of 2022 ended June 30, 2022. The Company held an analyst conference call on August 4, 2022 at 13.30 CET/07.30 EST.  To launch the audio webcast recording of the call please click on  this link . 

Implemented by the Centers for Disease Control and Prevention , the diagnosis code will accurately identify US patients with APDS, supporting care and research efforts LEIDEN, Netherlands , Aug. 2, 2022 /PRNewswire/ -- Pharming Group N.V. (" Pharming " or "the Company") (EURONEXT Amsterdam:

EMA  accelerated assessment allows a shorter review period for leniolisib from a standard 210 days to 150 days Pharming is on track to submit its Marketing Authorisation Application for leniolisib in H2 2022 LEIDEN, the Netherlands , Aug. 1, 2022 /PRNewswire/ -- Pharming Group N.V.

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will announce financial results for the six months ended 30 June 2022 on Thursday, August 4, 2022. The Company will host a presentation for analysts at 13:30 CET/07:30 EST on August 4, 2022.

Pharming announces that its Chief Executive Officer, Sijmen de Vries, will present at the Jefferies Healthcare Conference 2022, a hybrid meeting based in New York, at 22:00-22:30 CET/16:00-16:30 EDT on 9 June 2022. The Jefferies Healthcare Conference is a gathering of over 400 public and private

Pharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved. The shareholders adopted the financial statements for the 2021 financial year (agenda item 2.e); approved the proposal to grant discharge to the members of the Board of

Pharming Group N.V. presents its (unaudited) financial report for the first quarter of the year ended 31 March 2022. The Company will hold an analyst conference call at 13.30 CET/07.30 EST today (12 May).

Pharming confirms it will announce financial results for the first quarter of the year ended 31 March 2022 on Thursday, 12 May 2022. The Company will host a presentation for analysts at 13:30 CET/07:30 EST on 12 May 2022. Details for the presentation can be found below.  Conference call dial-in

An agreed Paediatric Investigation Plan (PIP) is the regulatory pathway to market authorization for leniolisib as a treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in children A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a

LEIDEN, Netherlands , April 1, 2022 /PRNewswire/ -- Pharming Group N.V. (" Pharming " or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces new data from the pivotal Phase II/III trial of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome